#United States #San Diego #Primrose Bio #RNA Polymerase #mRNA Production

Primrose Bio's Revolutionary RNA Polymerase

In a significant leap in biotechnology, Primrose Bio, Inc. has launched its latest innovation in RNA polymerase technology, the Prima RNApols™ ExTend Cap AU. This newly engineered polymerase is set to drastically improve the manufacturing process of self-amplifying mRNA vaccines and therapeutics, a critical advancement especially in our current landscape of vaccine development.

What is Prima RNApols™ ExTend Cap AU?

The ExTend Cap AU is not just another RNA polymerase; it is designed to optimize the production of self-amplifying mRNA (saRNA) by significantly enhancing the capping efficiency while minimizing the presence of double-stranded RNA (dsRNA) byproducts. The product is specifically engineered for AU cap analogs, which means that researchers can now produce high-yield, fully-capped mRNA with reduced requirements for capping reagents, template DNA, and RNA polymerase itself.

Key Features and Benefits

As outlined by Drew Burch, CEO of Primrose, this new enzyme presents a solution to some long-standing challenges in mRNA development and production:

1. High AU Capping Efficiency: The polymerase achieves optimal capping with less cap, which lowers the overall consumption of reagents. This translates to increased cost efficiency and a more sustainable production approach.

2. Ultra-low dsRNA Content: By minimizing unwanted in vitro transcription (IVT) byproducts, the necessity for downstream purification processes is substantially reduced. This is a game-changer for researchers seeking to streamline their work with saRNA products.

3. Higher Yield of saRNA: The polymerase significantly maximizes yield while preserving the integrity and fidelity of the mRNA, making it superior to traditional T7 polymerases.

4. Cost-efficient Manufacturing: By utilizing less template DNA, enzyme, and cap analog, developers can realize meaningful cost savings, thus making mRNA production more accessible.

With regulatory approvals already attained for saRNA products in regions such as Japan and Europe, the demand for improved manufacturing tools is critical. Primrose’s innovative enzyme evolution toolkit aligns precisely with these needs by empowering developers to create higher purity and fidelity mRNA products, ultimately addressing various health issues from infectious diseases to cancer.

Availability and Future Prospects

The Prima RNApols ExTend Cap AU is currently accessible for research use applications, while GMP-grade versions are produced and certified under ISO 13485:2016 for clinical and commercial mRNA manufacturing. Organizations at the forefront of pharmaceutical advancements, like Merck, Jazz Pharmaceuticals, and Alvogen, are already leveraging this technology to enhance their product offerings.

The launch of the ExTend Cap AU is not just a step forward for Primrose Bio; it marks a substantial progress for the biotechnology industry as a whole. With an increasing number of pharmaceutical companies utilizing Primrose's technologies, the potential to change the landscape of vaccine and therapeutic development is immense.

To learn more about this cutting-edge product, visit Primrose Bio's official website.

About Primrose Bio, Inc.

Founded with a mission to develop innovative solutions for the biopharmaceutical industry, Primrose Bio specializes in creating and commercializing advanced therapeutic manufacturing technologies. Their improvement in enzyme production, particularly through the Prima RNApols™ series, has already shown remarkable results, enabling higher yields and more efficient processes. The firm continues to fill critical gaps in production systems, promising scalable and effective manufacturing solutions for the future of healthcare.